3-fluoro-1H-indole-2-carboxylic acid | 942433-63-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-fluoro-1H-indole-2-carboxylic acid
• CAS: 942433-63-8
• 化学式: C₉H₆FNO₂
• mdl: MFCD18803460
• 分子量: 179.151
• InChiKey: NBRNUWKLKQQDQS-UHFFFAOYSA-N

物化性质

• 沸点：
  411.5±25.0 °C(Predicted)
• 密度：
  1.510±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PYRAZOLOSPIROCÉTONE ACÉTL-COA CARBOXYLASE
  申请人：PFIZER

  公开号：WO2009144554A1

  公开（公告）日：2009-12-03

  The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal.

  本发明提供了式(1)的化合物或所述化合物的药用可接受盐，其中R1、R2和R3如本文所述；其药物组合物；以及用于治疗通过抑制动物中的乙酰辅酶A羧化酶酶活性来调节的疾病、病症或障碍的使用方法。
• [EN] N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF<br/>[FR] DÉRIVÉ D'AMINE N-ACYLE CYCLIQUE OU SON SEL PHARMACEUTIQUEMENT ACCEPTABLE
  申请人：DAINIPPON SUMITOMO PHARMA CO

  公开号：WO2011111875A1

  公开（公告）日：2011-09-15

  The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurological diseases associated with cognitive dysfunction other than schizophrenia. N-Acyl cyclic amine derivatives of formula (1): wherein Ar1 and Ar2 are aryl or heteroaryl; V is nitrogen, or CR3; W1 is a single bond, -C(O)-, etc.; W2 is C1- alkylene; W3 is a single bond, methylene, -NH-, -CR4=CR5-, etc.; Ring Q is a group of formula (a) in which n is 0 or 1; m is 0 to 2; k is 1 to 3; Z is a single bond, methylene, oxygen, etc.; R1a, R1b and R1c are each, same or different, hydrogen, hydroxyl, halogen, cyano, C1-6 alkyl, etc.; or pharmaceutically acceptable salts thereof are provided.

  本发明提供了一种化合物，对于精神分裂症的阳性症状、阴性症状和认知功能障碍具有高效性，同时减少了传统的副作用风险，并对与精神分裂症以外的认知功能障碍相关的中枢神经系统疾病具有显著效果。提供了式（1）的N-酰基环胺衍生物，其中Ar1和Ar2是芳基或杂环芳基；V是氮或CR3；W1是单键，-C(O)-等；W2是C1-烷基；W3是单键，亚甲基，-NH-，-CR4=CR5-等；环Q是式（a）的一组，其中n为0或1；m为0到2；k为1到3；Z是单键，亚甲基，氧等；R1a、R1b和R1c分别是相同或不同的氢、羟基、卤素、氰基、C1-6烷基等；或其药用可接受盐。
• N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Maruyama Megumi

  公开号：US20120214790A1

  公开（公告）日：2012-08-23

  The present invention provides compounds which show high effectiveness against positive symptoms, negative symptoms and cognitive dysfunction in schizophrenia and reduce conventional side-effect risks as well as have remarkable effects for central neurological diseases associated with cognitive dysfunction other than schizophrenia. N-Acyl cyclic amine derivatives of formula (1): wherein Ar 1 and Ar 2 are aryl or heteroaryl; V is nitrogen, or CR 3 ; W 1 is a single bond, —C(O)—, etc.; W 2 is C 1 -alkylene; W 3 is a single bond, methylene, —NH—, —CR 4 ═CR 5 —, etc.; Ring Q is a group of formula (a) in which n is 0 or 1; m is 0 to 2; k is 1 to 3; Z is a single bond, methylene, oxygen, etc.; R 1a , R 1b and R 1c are each, same or different, hydrogen, hydroxyl, halogen, cyano, C 1-6 alkyl, etc.; or pharmaceutically acceptable salts thereof are provided.

  本发明提供了化合物，对于精神分裂症的阳性症状、阴性症状和认知功能障碍表现出高效性，并且降低了传统副作用风险，对于除精神分裂症以外的与认知功能障碍相关的中枢神经系统疾病具有显著的效果。公式（1）中的N-酰基环状胺衍生物，其中Ar1和Ar2是芳基或杂环芳基；V是氮或CR3；W1是单键，-C(O)-等；W2是C1-烷基；W3是单键，亚甲基，-NH-，-CR4═CR5-等；环Q是公式（a）的基团，在其中n为0或1；m为0到2；k为1到3；Z是单键，亚甲基，氧等；R1a，R1b和R1c分别相同或不同，是氢，羟基，卤素，氰基，C1-6烷基等；或其药学上可接受的盐。
• Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors
  申请人：Corbett Jeffrey W.

  公开号：US20110028390A1

  公开（公告）日：2011-02-03

  The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R 1 , R 2 , and R 3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal.

  本发明提供公式（1）的化合物或其药学上可接受的盐，其中R1，R2和R3如本文所述；其药物组合物；以及将其用于治疗动物中受乙酰辅酶A羧化酶酶抑制调节的疾病，状况或障碍。
• PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS
  申请人：Pfizer Inc.

  公开号：EP2297163A1

  公开（公告）日：2011-03-23